Published in Z Rheumatol on December 01, 2008
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2011) 4.78
[German patient version of the ASAS/EULAR recommendations for the management of ankylosing spondylitis]. Z Rheumatol (2010) 0.99
[Dissemination and evaluation of ASAS/EULAR recommendations for the management of ankylosing spondylitis in Europe]. Z Rheumatol (2009) 0.86
Trends in treatment and outcomes of ankylosing spondylitis in outpatient rheumatological care in Germany between 2000 and 2012. RMD Open (2015) 0.75
[ASAS/EULAR recommendations for the management of ankylosing spondylitis : evaluation of the 2010 update in the German-speaking area]. Z Rheumatol (2013) 0.75
Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess (2004) 29.45
Ankylosing spondylitis. Lancet (2007) 6.58
Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum (1998) 6.16
EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2004) 4.94
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31
Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int (2002) 2.95
Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis (2006) 2.72
EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis (2004) 2.48
First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis (2005) 2.21
Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol (1997) 2.11
Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study. J Rheumatol (1999) 1.70
Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis (2005) 1.70
Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev (2008) 1.61
Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Ann Rheum Dis (2004) 1.49
Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum (2007) 1.28
[Recommendations for the management of ankylosing spodylitis after ASAS/EULAR. Evaluation in the German language area]. Z Rheumatol (2006) 1.18
Responsible prescribing of opioids for the management of chronic pain. Drugs (2003) 1.17
The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol (2006) 1.03
Practice variation in the treatment of rheumatoid arthritis among German rheumatologists. J Rheumatol (2001) 1.03
Impact of ankylosing spondylitis on work and family life: comparisons with the US population. Arthritis Rheum (2008) 0.98
Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists. Ann Rheum Dis (2007) 0.94
Acute-phase response, clinical measures and disease activity in ankylosing spondylitis. Joint Bone Spine (2007) 0.88
Gut inflammation in the spondyloarthropathies. Curr Rheumatol Rep (2005) 0.88
[Patient education in rheumatologic care--a review]. Z Rheumatol (2008) 0.87
[Physiotherapeutic and rehabilitation therapy for ankylosing spondylitis. Status quo and are they still necessary in the age of anti-cytokine therapy?]. Z Rheumatol (2007) 0.85
[Inpatient aftercare in rheumatic diseases--concept, trial, and acceptance]. Rehabilitation (Stuttg) (2004) 0.79
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis (2009) 8.37
Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum (2000) 4.62
The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis (2009) 4.37
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31
Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology (2000) 3.90
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 3.17
Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis (2009) 3.15
Blindsight in normal observers. Nature (1995) 3.07
Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum (2003) 2.91
Neuronal activity in human primary visual cortex correlates with perception during binocular rivalry. Nat Neurosci (2000) 2.91
How to diagnose axial spondyloarthritis early. Ann Rheum Dis (2004) 2.91
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Ankylosing spondylitis: an overview. Ann Rheum Dis (2002) 2.71
Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease. Gut (2000) 2.71
Results of provider self-adjudication using the prudent layperson standard compared with the managed care organization's emergency department claim review process. Ann Emerg Med (2000) 2.64
Two distinct mechanisms for redistribution of lymphocyte surface macromolecules. I. Relationship to cytoplasmic myosin. J Cell Biol (1978) 2.54
Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol (2000) 2.45
Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology (1998) 2.38
ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 2.37
HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet (1998) 2.32
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis (2004) 2.26
Dead cell discrimination with 7-amino-actinomycin D in combination with dual color immunofluorescence in single laser flow cytometry. Cytometry (1992) 2.19
Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science (1993) 2.08
Attention activates winner-take-all competition among visual filters. Nat Neurosci (1999) 2.04
[The diagnosis of reactive arthritis. The possibilities and limits]. Dtsch Med Wochenschr (1993) 2.03
[German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm]. Z Rheumatol (2012) 1.91
Selectivity for polar, hyperbolic, and Cartesian gratings in macaque visual cortex. Science (1993) 1.88
Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis (2000) 1.85
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis (2013) 1.81
CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. J Clin Endocrinol Metab (1997) 1.78
Thermochemotherapy: synergism between hyperthermia (42-43 degrees) and adriamycin (of bleomycin) in mammalian cell inactivation. Proc Natl Acad Sci U S A (1975) 1.75
[Amendment of the structural quality for inpatient rheumatology. A forward-looking concept]. Z Rheumatol (2011) 1.74
Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis (2005) 1.70
The Crohn's disease-associated bacterial protein I2 is a novel enteric t cell superantigen. Immunity (2001) 1.69
Thromboembolic risk of postsplenectomy thrombocytosis. Arch Surg (1978) 1.67
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis (2012) 1.67
Ligand-induced association of surface immunoglobulin with the detergent-insoluble cytoskeletal matrix of the B lymphocyte. J Immunol (1982) 1.61
Infliximab treatment of severe ankylosing spondylitis: one-year followup. Arthritis Rheum (2001) 1.58
A study of the hematologic effects of chronic low-level exposure to benzene. J Occup Med (1991) 1.57
Isometric, isotonic, and isokinetic torque variations in four muscle groups through a range of joint motion. Phys Ther (1983) 1.57
Neural correlates of attention and working memory deficits in HIV patients. Neurology (2001) 1.55
Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis (2004) 1.53
Lateral interactions among membrane proteins. Implications for the organization of gap junctions. Biophys J (1987) 1.52
Pathogenesis of spondylarthropathies. Persistent bacterial antigen, autoimmunity, or both? Arthritis Rheum (1995) 1.52
Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences. Ann Rheum Dis (2005) 1.51
Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun (2000) 1.49
Eosinophilic fasciitis and myositis: use of imaging modalities for diagnosis and monitoring. Ann Rheum Dis (2008) 1.49
Crosslinking by ligands to surface immunoglobulin triggers mobilization of intracellular 45Ca2+ in B lymphocytes. J Cell Biol (1979) 1.49
A comparison of new bone formation in patients with ankylosing spondylitis and patients with diffuse idiopathic skeletal hyperostosis: a retrospective cohort study over six years. Arthritis Rheum (2011) 1.49
Brain areas specific for attentional load in a motion-tracking task. J Cogn Neurosci (2001) 1.48
Use of dynamic magnetic resonance imaging to detect sacroiliitis in HLA-B27 positive and negative children with juvenile arthritides. J Rheumatol (1998) 1.46
Probing bulk electronic structure with hard X-ray angle-resolved photoemission. Nat Mater (2011) 1.45
Use of NSAIDs and infection with Helicobacter pylori--what does the rheumatologist need to know? Rheumatology (Oxford) (2008) 1.45
Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis (2010) 1.44
Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis (2007) 1.44
Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis (2007) 1.43
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum (2005) 1.41
Early sacroiliitis in patients with spondyloarthropathy: evaluation with dynamic gadolinium-enhanced MR imaging. Radiology (1995) 1.40
MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis (2007) 1.40
[Arthritis of the atlanto-axial joint with inflammatory neck pain as a primary manifestation of seronegative rheumatoid arthritis]. Dtsch Med Wochenschr (2010) 1.40
Reverse transcriptase template switching during reverse transcriptase-polymerase chain reaction: artificial generation of deletions in ribonucleotide reductase mRNA. J Lab Clin Med (2001) 1.39
[Value of inpatient care in rheumatoid arthritis-an evidence based report]. Z Rheumatol (2004) 1.39
[Invasive pneumonia diagnosis in community-acquired pneumonia]. Pneumologie (1996) 1.39
Direct identification of critical clusters in chemical vapor deposition. Phys Rev Lett (2006) 1.38
Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford) (2004) 1.37
Overexpanded B cell clone mediating leukemic arthritis by abundant secretion of interleukin-1beta: a case report. Arthritis Rheum (1998) 1.37
Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis (2005) 1.37
Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis (2005) 1.35
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis (2010) 1.34
A community-wide outbreak of hepatitis A: risk factors for infection among homosexual and bisexual men. Am J Med (1995) 1.34
Ankylosing spondylitis--cardiac manifestations. Clin Exp Rheumatol (2002) 1.33
Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum (2010) 1.33
Gender differences in the functional organization of the brain for working memory. Neuroreport (2000) 1.33
Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. Ann Rheum Dis (2004) 1.33
[New therapeutic viewpoints on ulcus molle]. Hautarzt (1975) 1.32
Limited B cell repertoire in severe combined immunodeficient mice engrafted with peripheral blood mononuclear cells derived from immunodeficient or normal humans. J Clin Invest (1991) 1.32
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis (2008) 1.31
Spontaneous redistribution of surface immunoglobulin in the motile B lymphocyte. J Exp Med (1976) 1.31
Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in Hashimoto's thyroiditis and Addison's disease. J Clin Endocrinol Metab (1997) 1.31
Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions. Ann Rheum Dis (2007) 1.30
Anatomic structures involved in early- and late-stage sacroiliitis in spondylarthritis: a detailed analysis by contrast-enhanced magnetic resonance imaging. Arthritis Rheum (2003) 1.29
Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol (2002) 1.29
Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis (2001) 1.29
Identification of a novel mycobacterial histone H1 homologue (HupB) as an antigenic target of pANCA monoclonal antibody and serum immunoglobulin A from patients with Crohn's disease. Infect Immun (1999) 1.28
ASAS/WHO ICF Core Sets for ankylosing spondylitis (AS): how to classify the impact of AS on functioning and health. Ann Rheum Dis (2010) 1.28
No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study. Arthritis Rheum (1999) 1.28
Three-dimensional analysis of shear wave propagation observed by in vivo magnetic resonance elastography of the brain. Acta Biomater (2006) 1.28
Measuring esophageal motility with a new intraluminal impedance device. First clinical results in reflux patients. Scand J Gastroenterol (1994) 1.27
Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. Arthritis Rheum (1997) 1.27
How a gap junction maintains its structure. Nature (1984) 1.26
Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum (2005) 1.25
Usage of the coreceptors CCR-5, CCR-3, and CXCR-4 by primary and cell line-adapted human immunodeficiency virus type 2. J Virol (1997) 1.24
Vision and attention: the role of training. Nature (1998) 1.24
T cell cytokine pattern in the joints of patients with Lyme arthritis and its regulation by cytokines and anticytokines. Arthritis Rheum (1997) 1.23
B lymphocyte biology studied with anti-Ig antibodies. Immunol Rev (1980) 1.22
The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis. Rheumatology (Oxford) (2005) 1.22
Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis (2011) 1.21
Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Ann Rheum Dis (2005) 1.21